Evidence map›Paper›PMID 41733536›Full record

ArticleActa oncologica (Stockholm, Sweden)2026

'Crossing borders' in data standardisation: application of OMOP CDM in an international clinical trial network in precision cancer medicine.

Maria Martin Agudo, Henk Van der Pol, Gabriel Bratseth Stav, Tina Kringelbach, Katarina Puco, Åsmund Flobak, Hans Gelderblom, Kjetil Taskén, Gro Live Fagereng, Eivind Hovig and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta oncologica (Stockholm, Sweden), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Maria Martin AgudoInstitute for Cancer Research, Oslo University Hospital, Oslo, Norway. m.m.agudo@ous-research.no.ORCID 0000-0003-3605-9963
Henk Van der PolDepartment of Medical Oncology, Leiden University Medical Center, Leiden, The Netherlands; Mathematical Institute, Leiden University, Leiden, The Netherlands.ORCID 0009-0009-9524-9573
Gabriel Bratseth StavInstitute for Cancer Research, Oslo University Hospital, Oslo, Norway.ORCID 0009-0000-2265-4222
Tina KringelbachDepartment of Oncology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.ORCID 0009-0002-7886-707X
Katarina PucoInstitute for Cancer Research, Oslo University Hospital, Oslo, Norway.ORCID 0000-0002-7681-5949
Åsmund FlobakDepartment of Oncology, Trondheim University Hospital, Trondheim, Norway.ORCID 0000-0002-3357-425X
Hans GelderblomDepartment of Medical Oncology, Leiden University Medical Center, Leiden, The Netherlands.ORCID 0000-0001-9270-8636
Kjetil TaskénInstitute for Cancer Research, Oslo University Hospital, Oslo, Norway.ORCID 0000-0003-2841-4697
Gro Live FagerengInstitute for Cancer Research, Oslo University Hospital, Oslo, Norway.ORCID 0000-0003-2600-6606
Eivind HovigInstitute for Cancer Research, Oslo University Hospital, Oslo, Norway.ORCID 0000-0002-9103-1077
PRIME-ROSE Consortium

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID41733536
PMCPMC12946775

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.